
Opinion|Videos|December 2, 2024
Dosing Frequency and Formulary Decisions for Bispecific Antibodies
Key Takeaways
- Weekly dosing may provide consistent therapeutic levels, while biweekly dosing reduces hospital visits, affecting patient convenience and healthcare resource allocation.
- Formulary decisions should evaluate efficacy, safety profiles, cost-effectiveness, and integration potential into existing treatment regimens.
Panelists discuss how when selecting between weekly and biweekly dosing schedules for talquetamab and teclistamab in multiple myeloma treatment, health care institutions must carefully weigh factors like patient convenience, monitoring requirements, resource utilization, and total cost of care alongside clinical outcomes to determine optimal treatment pathways for both patient and health system benefits.
Advertisement
Episodes in this series

Video content above is prompted by the following
- Specifically, for talquetamab and teclistamab, how has your institution standardized selection of weekly or biweekly dosing, and how do these different dosing frequencies differ in terms of impact on the health system and patient?
- What additional factors should be considered when making formulary decisions regarding the 3 currently available bispecific antibodies?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
2
Brain Imaging Study Links Long COVID to Dopamine Neuron Injury, Pointing to Repurposed Treatments
3
Bringing Bispecific Therapy Into the Outpatient Community Oncology Setting
4
Chronic Low Back Pain Treatments Must Be Weighed Against Risk, Cost, and Limited Benefit
5






































































































